| 2003 |
ReproCell Co., Ltd. was established as a regenerative medicine venture originating from Kyoto University and the University of Tokyo. |
| 2003 |
ReproCell Co., Ltd. was established in 2003 as a regenerative medicine venture originating from Kyoto University and the University of Tokyo. |
| 2003-02 |
ReproCell Co., Ltd. established. |
| 2005-04 |
Started sales of Primate ES cell medium for ES cell culture. |
| 2006-12 |
Registered as a sanitary inspection laboratory and began contract clinical testing services. |
| 2007-11 |
Used Primate ES cell medium to establish the world's first human iPS cell line. |
| 2007-11 |
Established ReproCELL USA. |
| 2013 |
It went public in its 10th year of operation. |
| 2013 |
Listed on JASDAQ. |
| 2014-02 |
Established the venture capital fund 'Cell Innovation Partners' jointly with New Enterprise Investment Co., Ltd., focusing on next-generation drug discovery and medical business. |
| 2014-02 |
In February 2014, established the venture capital fund 'Cell Innovation Partners' jointly with New Enterprise Investment Co., Ltd. |
| 2014-02 |
Established the venture capital fund 'Cell Innovation Partners' in collaboration with New Enterprise Investment Co., Ltd. |
| 2014-02 |
Established the venture capital fund 'Cell Innovation Partners' in collaboration with New Enterprise Investment. |
| 2014-07 |
Acquired Reinnervate (UK) as a subsidiary. |
| 2014-07 |
In July 2014, acquired Reinnervate (UK) as a subsidiary. |
| 2014-07 |
Acquired Reinnervate (UK) as a subsidiary. |
| 2014-09 |
Acquired BioServe (USA) as a subsidiary. |
| 2014-10 |
Acquired Stemgent (USA)'s iPS cell business unit and renamed the subsidiary to Stemgent. |
| 2014-10 |
Acquired Stemgent (USA)'s iPS cell business unit. |
| 2015-11 |
Acquired Biopta (UK) as a subsidiary. |
| 2016-07 |
Two UK subsidiaries merged and changed their name to REPROCELL EUROPE. |
| 2016-09 |
Two US subsidiaries merged and changed their name to REPROCELL USA. |
| 2018-04 |
Acquired Bioserve India (REPROCELL INDIA) as a subsidiary. |
| 2018-04 |
In April 2018, acquired Bioserve India (REPROCELL INDIA) as a subsidiary. |
| 2018-04 |
Established the joint venture 'MAGiQ Therapeutics Co., Ltd.' with Q Therapeutics Inc. (USA) in Japan. |
| 2018-04 |
Established the joint venture 'MAGiQ Therapeutics Co., Ltd.' with Q Therapeutics Inc. (USA) in Japan and began developing regenerative medicine products utilizing iPS cell-derived glial progenitor cells. |
| 2019-05 |
Opened the Reprocell Regenerative Medicine Center in Tonemachi. |
| 2019-05 |
Acquired Bioserve India as a subsidiary (REPROCELL INDIA). |
| 2020-02 |
Commenced clinical trials of the regenerative medicine product StemKaimar®. |
| 2020-12 |
Launched the personal iPS cell production and storage service 'Personal iPS'. |
| 2020-12 |
Commenced administration to the first subject in Phase II clinical trials and completed the trial in May 2022. |
| 2021-03 |
Obtained a 'Special Cell Processing Product Manufacturing Permit' from the Ministry of Health, Labour and Welfare Kanto Shinetsu Health Bureau. |
| 2021-03 |
Launched the personal iPS cell production and storage service 'Personal iPS'. |
| 2022-05 |
Completion of Phase II clinical trials. |
